RESUMEN

In brief: Ghrelin signals to the hypothalamus inhibit reproduction during times of food scarcity. In this study, we demonstrate that ghrelin impairs sperm quality in male mice. Abstract: Ghrelin (GHRL) is an orexigenic peptide that has been investigated as one of the signals responsible for the reproductive performance of mammals under fluctuating metabolic conditions. Central GHRL administration impairs spermatogenesis in mice by regulating the hypothalamic-pituitary-gonadal axis function. In the present study, the hypothalamus role as a mediator of GHRL effects on sperm fertilizing capacity and male sexual behavior was evaluated. After 42 days of hypothalamic GHRL infusion or artificial cerebrospinal fluid, in vitro and in vivo sperm fertilizing capacity, testicular α-tubulin, speriolin gene expression and spermatic α-tubulin protein were evaluated. Hypothalamic expression of genes Kiss1, Gpr54 and Gnrh was also studied. The second group of animals was infused with one time only GHRL or artificial cerebrospinal fluid into the hypothalamus to evaluate the effects on sexual behavior. Results demonstrated that chronic GHRL administration to male mice significantly increased the percentages of pre-implantation embryo loss and the number of post-implantation embryo loss. In relation to the gene expression, our results show a relative decrease of Kiss1, Gpr54 and Spatc1. Although no significant differences were observed in the quantitative expression of α-tubulin protein, qualitative changes in its expression pattern were observed. In addition, a dual effect on sexual behavior was observed: 40% of the treated animals showed a significant reduction in the number of mounts and intromissions, while a 60% showed a significant decrease in ejaculation latency vs control animals. In conclusion, our results provide evidence that central GHRL administration possibly induces failure in embryo development and/or implantation in the females mated with treated males, possibly because of a negative effect in the α-tubulin pattern.

Asunto(s)

Aborto Espontáneo , Tubulina (Proteína) , Masculino , Ratones , Animales , Femenino , Humanos , Embarazo , Pérdida del Embrión , Semen , Conducta Sexual , Espermatozoides , Mamíferos

RESUMEN

CONTEXT AND AIMS: We have demonstrated that ghrelin (Ghrl) participates in fetal programming, since intragestational hyperghrelinaemia increased pup's growth and a Ghrl-receptor antagonist accelerated offspring's sexual maturation and impaired their adult reproductive function. Now, we aim to analyse if these phenotypic changes (found in F1) also occurred in F2 and/or F3 generations. METHODS: We treated mice dams (F0), with 4nmol/animal/day of Ghrl or 6nmol/animal/day of an antagonist [Ant:(d -Lys3)GHRP6] from day 1 of pregnancy until delivery. When F1 female pups reached adulthood, they were paired to obtain F2, and subsequently, F2 females were paired to obtain F3. Parameters evaluated in F2 and F3 pups were: growth, physical development, neurobiological maturation, puberty onset and in adulthood, reproductive function. KEY RESULTS: The F2 and F3 Ant groups showed a significant increase in litter size. Although no differences were detected in the weight of these pups at birth, in adulthood, they were heavier. At F3, pups from the Ant group showed advanced incisors eruption and eye opening compared to controls. Furthermore, F3 male pups from the Ant group showed earlier testis descent, although in adulthood, these males exhibited reduced sperm concentration in comparison to Ghrl. No differences were detected in F2 or F3 females regarding puberty onset or reproduction. CONCLUSIONS AND IMPLICATIONS: Some fetal programming effects of Ghrl seen in F1, also appeared transgenerationally. Since many women at reproductive age suffer from conditions with reduced Ghrl levels (i.e. obesity or polycystic ovarian syndrome), these results could be relevant to the health of their descendants.

Asunto(s)

Ghrelina , Efectos Tardíos de la Exposición Prenatal , Animales , Femenino , Ghrelina/farmacología , Humanos , Tamaño de la Camada , Masculino , Ratones , Parto , Embarazo , Reproducción , Semen

RESUMEN

To explore in mice if a 15% food restriction protocol during pregnancy programs the offspring postnatal development, with emphasis on reproductive function, and to assess if ghrelin (Ghrl) administration to mouse dams exerts effects that mimic those obtained under mild caloric restriction. Mice were 15% food-restricted, injected with 4 nmol/animal/day of Ghrl, or injected with the vehicle (control) thorough pregnancy. After birth, the pups did not receive further treatment. Pups born from food-restricted dams (FR pups) were lighter than Ghrl pups at birth, but reached normal weight at adulthood. Ghrl pups were heavier at birth and gained more weight than control pups (C pups). This effect was not associated with plasma IGF-1. FR pups showed a delay in pinna detachment and eye opening, while an advance was observed in Ghrl pups. FR pups showed also impairment in the surface-righting reflex. In both female FR and Ghrl pups, there was an advance in vaginal opening and, in adulthood, FR pups showed a significant decrease in their own litter size and plasma progesterone, and an increase in embryo loss. A delay in testicular descent was evident in male Ghrl pups. Changes in puberty onset were not associated with differences in the expression of Kiss1 in hypothalamic nuclei. Finally, in adulthood, FR pups showed a significant decrease in sperm quality. In conclusion, a mild food restriction thorough gestation exerted programming effects on the offspring, affecting also their reproductive function in adulthood. These effects were not similar to those of intragestational Ghrl administration.

Asunto(s)

Restricción Calórica/métodos , Desarrollo Fetal/fisiología , Ghrelina/administración & dosificación , Efectos Tardíos de la Exposición Prenatal/genética , Desarrollo Sexual/fisiología , Animales , Animales Recién Nacidos , Vías de Administración de Medicamentos , Femenino , Desarrollo Fetal/efectos de los fármacos , Masculino , Ratones , Embarazo , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Desarrollo Sexual/efectos de los fármacos

RESUMEN

Objectives: To determine prevalence of psychostimulants (PS) consumption among medical students of National University of Córdoba (UNC) trying to improve their concentration and alertness when studying as well as potentially related factors. Methods: Methods: urvey was designed. Absolute and relative frequency was calculated for qualitative variables; and mead, median, mode and range were obtained for quantitative ones. InfoStat software was used and Chi-square and Student t tests were applied when appropriate. Results: 99,15% consumed a PS, being coffee predominant in 93,05%, mate 91,02%, tea 74,75%, chocolate 70%, soft drinks 58,64%, energy drinks 37,97%, tobacco 22,71%, Cafiaspirina® 13%, Arriba!quenotebochen® 9%, coca leaves 8%. 8,3% referred modafinil and methylphenidate consumption and 45% of them perceived an improvement of their academic performance after this. Consuming these drugs was associated to masculine sex (p=0,0275), older age, (p˂0,0001), not professing any religion (p=0,0004), higher courses (p˂0,0001), more academic difficulty (p˂0,0001), delay in the degree (p=0,0009), less than 4 hours of sleep before and exam (p=0,0002), psychological or psychiatric diagnosis (p=0,0017), anxiety disorder (p=0,0068), depressive disorder (p=0,0275) and higher consumption level of caffeine (p˂0,0268). No association was found with working, practicing sports or living with their families. Conclusion: PS consumption to improve academic performance is a usual practice among the students who integrated the sample.

---

Objetivos: Determinar prevalencia del consumo de psicoestimulantes (PS) por estudiantes de Medicina de la Universidad Nacional de Córdoba (UNC) buscando mejorar su concentración y nivel de alerta al estudiar, y potenciales factores asociados. Métodos: Estudio epidemiológico observacional, analítico, prospectivo, de corte transversal con abordaje cuali-cuantitativo. La población estuvo conformada por todos los estudiantes de Medicina de la UNC de 2018. Se elaboró una encuesta anónima de 23 preguntas. Se determinó frecuencia absoluta y porcentual para las variables cualitativas y para las cuantitativas se obtuvo media, moda, mediana y rango. Se empleó el programa InfoStat y se aplicaron las pruebas Chi-cuadrado y t de Student según correspondiera. Resultados: El 99,15% consumió algún PS con predominio de café en el 93,05%, mate 91,02%, té 74,75%, chocolate 70%, gaseosas colas 58,64%, bebidas energizantes 37,97%, tabaco 22,71%, Cafiaspirina® 13%, Arriba!quenotebochen® 9%, hojas de coca 8%. El 8,3% refirió consumo de modafinilo y/o metilfenidato y el 45% de estos percibió que sus resultados académicos mejoraron tras el consumo. El consumo de estos fármacos se asoció con sexo masculino (p=0,0275), mayor edad (p˂0,0001), no practicar ninguna religión (p=0,0004), mayor avance en la carrera (p˂0,0001), mayor dificultad académica (p˂0,0001), atraso en la carrera (p=0,0009), menos de 4 horas de sueño pre-examen (p=0,0002), diagnóstico psicológico o psiquiátrico (p=0,0017), trastorno ansioso (p=0,0068), trastorno depresivo (p=0,0275) y mayor consumo de cafeína (p˂0,0268). No se encontró asociación con trabajo, deporte o convivientes. Conclusiones: El consumo de PS como potenciadores cognitivos es una práctica habitual entre los estudiantes que conformaron la muestra.

Asunto(s)

Estimulantes del Sistema Nervioso Central , Estudiantes de Medicina , Cafeína , Humanos , Encuestas y Cuestionarios , Universidades

RESUMEN

It has been demonstrated that food intake and reproductive physiology are both simultaneously modulated to optimize reproductive success under fluctuating metabolic conditions. Ghrelin (GHRL) is an orexigenic peptide identified as the endogenous ligand of the growth hormone secretagogue receptor that is being investigated for its potential role on reproduction. Considering that data available so far are still limited and characterization of GHRL action mechanism on the reproductive system has not been fully elucidated, we studied the participation of hypothalamus in GHRL effects on sperm functional activity, plasma levels of gonadotropins and histological morphology in mice testes after hypothalamic infusion of 0.3 or 3.0 nmol/day GHRL or artificial cerebrospinal fluid (ACSF) at different treatment periods. We found that GHRL 3.0 nmol/day administration for 42 days significantly reduced sperm concentration (GHRL 3.0 nmol/day = 14.05 ± 2.44 × 106/mL vs ACSF = 20.33 ± 1.35 × 106/mL, P < 0.05) and motility (GHRL 3.0 nmol/day = 59.40 ± 4.20% vs ACSF = 75.80 ± 1.40%, P < 0.05). In addition, histological studies showed a significant decrease percentage of spermatogonia (GHRL 3.0 nmol/day = 6.76 ± 0.68% vs ACSF = 9.56 ± 0.41%, P < 0.05) and sperm (GHRL 3.0 nmol/day = 24.24 ± 1.92% vs ACSF = 31.20 ± 3.06%, P < 0.05). These results were associated with a significant reduction in luteinizing hormone and testosterone plasma levels (P < 0.05). As GHRL is an orexigenic peptide, body weight and food intake were measured. Results showed that GHRL increases both parameters; however, the effect did not last beyond the first week of treatment. Results presented in this work confirm that central GHRL administration impairs spermatogenesis and suggest that this effect is mediated by inhibition of hypothalamic-pituitary-gonadal axis.

Asunto(s)

Ghrelina/fisiología , Gonadotropinas Hipofisarias/sangre , Hipotálamo/fisiología , Espermatogénesis , Testosterona/sangre , Animales , Peso Corporal , Ingestión de Alimentos , Masculino , Ratones , Espermatozoides/fisiología , Testículo/ultraestructura

RESUMEN

RATIONALE: In response to stress, corticotropin releasing hormone (CRH) and vasopressin (AVP) are released from the hypothalamus, activate their receptors (CRHR1, CRHR2 or AVPr1b), and synergistically act to induce adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Overstimulation of this system has been frequently associated with major depression states. OBJECTIVE: The objective of the study is to assess the role of AVP and CRH receptors in fluoxetine and venlafaxine effects on the expression of depression-related behavior. METHODS: In an animal model of depression (olfactory bulbectomy in mice, OB), we evaluated the effects of fluoxetine or venlafaxine (both 10 mg/kg/day) chronic administration on depression-related behavior in the tail suspension test. Plasma levels of AVP, CRH, and ACTH were determined as well as participation of their receptors in the expression of depression related-behavior and gene expression of AVP and CRH receptors (AVPr1b, CRHR1, and CRHR2) in the pituitary gland. RESULTS: The expression of depressive-like behavior in OB animals was reversed by treatment with both antidepressants. Surprisingly, OB-saline mice exhibited increased AVP and ACTH plasma levels, with no alterations in CRH levels when compared to sham mice. Chronic fluoxetine or venlafaxine reversed these effects. In addition, a significant increase only in AVPr1b gene expression was found in OB-saline. CONCLUSION: The antidepressant therapy used seems to be more likely related to a reduced activation of AVP rather than CRH receptors, since a positive correlation between AVP levels and depressive-like behavior was observed in OB animals. Furthermore, a full restoration of depressive behavior was observed in OB-fluoxetine- or venlafaxine-treated mice only when AVP was centrally administered but not CRH.

Asunto(s)

Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Fluoxetina/uso terapéutico , Receptores de Vasopresinas/metabolismo , Clorhidrato de Venlafaxina/uso terapéutico , Hormona Adrenocorticotrópica/sangre , Animales , Antidepresivos/farmacología , Arginina Vasopresina/sangre , Conducta Animal/efectos de los fármacos , Hormona Liberadora de Corticotropina/sangre , Trastorno Depresivo/etiología , Trastorno Depresivo/metabolismo , Modelos Animales de Enfermedad , Fluoxetina/farmacología , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Masculino , Ratones , Bulbo Olfatorio/cirugía , Receptores de Hormona Liberadora de Corticotropina/metabolismo , Transducción de Señal/efectos de los fármacos , Clorhidrato de Venlafaxina/farmacología

RESUMEN

Ghrelin (Ghr) is an orexigenic peptide that is being investigated for its potential role in development of anxiety-like behavior and modulation of depressive-like symptoms induced by bilateral olfactory bulbectomy (OB) in rodents. Olfactory bulbectomy is an animal model useful to study of depression and Ghr could be an alternative therapeutic tool in depression therapy. We studied the effects of intracerebroventricular (i.c.v.) Ghr administration on the expression of hypothalamic genes related to depression and mood (delta opioid receptor (DOR), mu opioid receptor (MOR) and kappa opioid receptor (KOR), lutropin-choriogonadotropic hormone receptor (LHCGR), serotonin transporter (SERT), interleukin 1 beta (IL-1b), vasopressin (AVP) and corticotrophin releasing hormone (CRH)) in OB animals, as well as changes in plasma levels of AVP, CRH and adenocorticotropic hormone (ACTH). We found that acute Ghr 0.3 nmol/µl administration increases gene expression of DOR, SERT and LHCGR in OB mice and decreased expression of IL-1b, suggesting that these genes could be involved in the antidepressant-like effects of Ghr. In addition, OB animals exhibit high AVP gene expression and elevated plasma concentrations of AVP and ACTH and acute Ghr 0.3 nmol/µl administration reduces AVP gene expression and the concentration of these hormones, suggesting that peptide-effects on depressive-like behavior could be mediated at least in part via AVP. In conclusion, this study provides new evidence about genes, receptors and hormones involved in the antidepressant mechanism/s induced by Ghr in OB animals.

Asunto(s)

Antidepresivos/uso terapéutico , Depresión/tratamiento farmacológico , Regulación de la Expresión Génica/efectos de los fármacos , Ghrelina/uso terapéutico , Hormona Adrenocorticotrópica/sangre , Análisis de Varianza , Animales , Antidepresivos/farmacología , Arginina Vasopresina/sangre , Hormona Liberadora de Corticotropina/sangre , Depresión/sangre , Depresión/etiología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Ghrelina/farmacología , Interleucina-1beta/metabolismo , Ratones , Bulbo Olfatorio/lesiones , Receptores de HL/genética , Receptores de HL/metabolismo , Receptores Opioides/genética , Receptores Opioides/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo

RESUMEN

This study aims to examine the antidepressant-like action of Ghrelin (Ghr), a hormone synthesized predominantly by gastrointestinal endocrine cells and released during periods of negative energy balance, in two behavioral models: tail suspension test (TST), a predictive model of antidepressant activity, and the olfactory bulbectomy (OB), an established animal model of depression. The reduction in the immobility time in the TST was the parameter used to assess antidepressant-like effect of Ghr. The depressive-like behavior in olfactory bulbectomized mice was inferred through the increase in the immobility time in the TST and the hyperlocomotor activity in the open-field test. Ghr produced antidepressant-like effect in TST (0.3 nmol/µl, i.c.v.), and reversed OB-induced depressive-like behavior. In conclusion, these results provide clear evidence that an acute administration of ghrelin produce antidepressant-like effect in the TST and OB.

Asunto(s)

Conducta Animal/efectos de los fármacos , Depresión/tratamiento farmacológico , Ghrelina/administración & dosificación , Animales , Antidepresivos/administración & dosificación , Antidepresivos/farmacología , Femenino , Ghrelina/farmacología , Suspensión Trasera , Pérdida de Tono Postural/efectos de los fármacos , Ratones , Bulbo Olfatorio/efectos de los fármacos , Bulbo Olfatorio/cirugía

RESUMEN

Serotonin-specific reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) are antidepressant drugs commonly used to treat a wide spectrum of mood disorders (Wong and Licinio, 2001). Although they have been clinically used for more than 50 years, the molecular and cellular basis for the action of SSRIs and SNRIs is not clear. Considering that the changes in gene expression involved in the action of antidepressant drugs on memory have not been identified, in this study we investigated the impact of chronic treatment with a SSRI (fluoxetine) and a SNRI (venlafaxine) on the mRNA expression of genes related to memory cascade in the mouse hippocampus, namely, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), nitric oxide synthase 1 (NOS1), neurotrophic tyrosine kinase receptor type 2 (TrKB), mitogen-activated protein kinases (MAPK/ERK) and serotonin transporter (SERT). Animals treated with fluoxetine 10 mg/Kg/day for 28 days showed a significant decrease in the percentage of time spent in the novel object recognition test (p≤0.005) and induced MAPK1/ERK2 down-regulation (p=0.005). Our results suggest that the effect on cognition could probably be explained by fluoxetine interference in the MAPK/ERK memory pathway. In contrast, chronic treatment with venlafaxine did not reduce MAPK1/ERK2 expression, suggesting that MAPK1/ERK2 down-regulation is not a common effect of all antidepressant drugs. Further studies are needed to examine the effect of chronic fluoxetine treatment on the ERK-CREB system, and to determine whether there is a causal relationship between the disruption of the ERK-CREB system and the effect of this antidepressant on memory performance.

Asunto(s)

Encéfalo/efectos de los fármacos , Ciclohexanoles/farmacología , Fluoxetina/farmacología , Reconocimiento en Psicología/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Animales , Encéfalo/metabolismo , Expresión Génica/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/genética , Masculino , Ratones , Óxido Nítrico Sintasa de Tipo I/genética , Óxido Nítrico Sintasa de Tipo I/metabolismo , Receptor trkB/genética , Receptor trkB/metabolismo , Receptores AMPA/genética , Receptores AMPA/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Clorhidrato de Venlafaxina